Making incurable pancreatic cancer curable

Abstract

Pancreatic cancer is one of the deadliest malignancies, with limited effectiveness of standard therapies, resulting in little improvement in the 5-year survival rate over the past few decades. However, advanced radiotherapy techniques and emerging treatment modalities, such as immunotherapy and targeted therapy, are showing tremendous potential as effective treatment options for pancreatic cancer patients who were previously considered incurable. This review summarizes the current advances and challenges in pancreatic cancer treatment strategies and proposes further optimization directions, aiming to provide insights into the cure of incurable pancreatic cancer.

Keywords

pancreatic cancer / early screening / radiotherapy / immunotherapy / targeted therapy / tumor microenvironment

References

[1] NIH Surveillance EAER . Cancer Stat Facts: Pancreatic Cancer. 2023. Accessed June 14, 2023. https://seer.cancer.gov/statfacts/html/pancreas.html

[2] Siegel RL , Miller KD , Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70 (1): 7- 30.

[3] Yu S , Zhang C , Xie KP . Therapeutic resistance of pancreatic cancer: roadmap to its reversal. Biochim Biophys Acta Rev Cancer. 2021; 1875 (1): 188461.

[4] Labori KJ , Katz MH , Tzeng CW , et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma—a population-based cohort study. Acta Oncol. 2016; 55 (3): 265- 277.

[5] Kartal E , Schmidt TSB , Molina-Montes E , et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022; 71 (7): 1359- 1372.

[6] Hou J , Li X , Xie KP . Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol Cancer. 2021; 20 (1): 34.

[7] Singhi AD , Wood LD . Early detection of pancreatic cancer using DNA-based molecular approaches. Nat Rev Gastroenterol Hepatol. 2021; 18 (7): 457- 468.

[8] Takano S , Fukasawa M , Enomoto N . Molecular assessment of endoscopically collected pancreatic juice and duodenal fluid from patients with pancreatic diseases. Dig Endosc. 2023; 35 (1): 19- 32.

[9] Kaźmierczak-Siedlecka K , Stachowska E , Folwarski M , Przewłócka K , Makarewicz W , Bryl E . The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2021; 25 (23): 7275- 7284.

[10] Ballehaninna UK , Chamberlain RS . The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012; 3 (2): 105- 119.

[11] Azizian A , Rühlmann F , Krause T , et al. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020; 10 (1): 1332.

[12] Luo G , Jin K , Deng S , et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2021; 1875 (2): 188409.

[13] Luo G , Liu C , Guo M , et al. Potential biomarkers in Lewis negative patients with pancreatic cancer. Ann Surg. 2017; 265 (4): 800- 805.

[14] Xu HX , Liu L , Xiang JF , et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery. 2017; 161 (2): 373- 384.

[15] Gao Y , Wang M , Guo X , et al. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. PLoS One. 2021; 16 (9): e0250539.

[16] Tartaglione S , Mancini P , Viggiani V , Chirletti P , Angeloni A , Anastasi E . PIVKA-II: a biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma. PLoS One. 2021; 16 (5): e0251656.

[17] O'Neill RS , Emmanuel S , Williams D , Stoita A . Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort. World J Gastroenterol. 2020; 26 (14): 1660- 1673.

[18] Kosanam H , Prassas I , Chrystoja CC , et al. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics. 2013; 12 (10): 2820- 2832.

[19] He Q , Liu Z , Wang J . Targeting KRAS in PDAC: a new way to cure it? Cancers. 2022; 14 (20): 4982.

[20] Sausen M , Phallen J , Adleff V , et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015; 6: 7686.

[21] Giampieri R , Piva F , Occhipinti G , et al. Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS One. 2019; 14 (5): e0215990.

[22] Madhavan B , Yue S , Galli U , et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015; 136 (11): 2616- 2627.

[23] Machida T , Tomofuji T , Maruyama T , et al. miR‑1246 and miR‑4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. Oncol Rep. 2016; 36 (4): 2375- 2381.

[24] Seshacharyulu P , Baine MJ , Souchek JJ , et al. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2017; 1868 (1): 69- 92.

[25] Liu J , Lee P , McGee HM , et al. Advances in radiation oncology for pancreatic cancer: an updated review. Cancers. 2022; 14 (23): 5725.

[26] Wen X , Chen S , Chen X , et al. ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway. Front Oncol. 2022; 12: 887068.

[27] Xia N , Yang N , Shan Q , et al. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. J Cell Mol Med. 2022; 26 (8): 2322- 2336.

[28] Ding X , Dionisi F , Tang S , et al. A comprehensive dosimetric study of pancreatic cancer treatment using three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), volumetric-modulated radiation therapy (VMAT), and passive-scattering and modulated- scanning proton therapy (PT). Med Dosimetry. 2014; 39 (2): 139- 145.

[29] Goto Y , Nakamura A , Ashida R , et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiation Oncol. 2018; 13 (1): 118.

[30] Song W , Hsu JC , Lan X , Cai W . Optical image-guided therapy of pancreatic cancer with an ultra-small bispecific protein. Eur J Nucl Med Mol Imaging. 2023; 50 (6): 1560- 1563.

[31] Chen X , Lee HY , Tang TT , et al. The novel use of IL-28 as an effective radiosensitizer in pancreatic cancer. Anticancer Res. 2023; 43 (5): 1885- 1890.

[32] Zhou Y , Xu Y , Lu L , et al. Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage. Theranostics. 2019; 9 (22): 6665- 6675.

[33] Parikh AR , Szabolcs A , Allen JN , et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nature Cancer. 2021; 2 (11): 1124- 1135.

[34] Kobeissi JM , Simone CB , Lin H , Hilal L , Hajj C . Proton therapy in the management of pancreatic cancer. Cancers. 2022; 14 (11): 2789.

[35] Ng S , Herman J . Stereotactic radiotherapy and particle therapy for pancreatic cancer. Cancers. 2018; 10 (3): 75.

[36] Liermann J , Shinoto M , Syed M , Debus J , Herfarth K , Naumann P . Carbon ion radiotherapy in pancreatic cancer: a review of clinical data. Radiother Oncol. 2020; 147: 145- 150.

[37] Matsumoto S , Kishimoto S , Saito K , et al. Metabolic and physiologic imaging biomarkers of the tumor microenvironment predict treatment outcome with radiation or a hypoxia-activated prodrug in mice. Cancer Res. 2018; 78 (14): 3783- 3792.

[38] Liu YT , Sun ZJ . Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021; 11 (11): 5365- 5386.

[39] Ullman NA , Burchard PR , Dunne RF , Linehan DC . Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022; 40 (24): 2789- 2805.

[40] Mukherji R , Debnath D , Hartley ML , Noel MS . The role of immunotherapy in pancreatic cancer. Curr Oncol. 2022; 29 (10): 6864- 6892.

[41] Wu J , Cai J . Dilemma and challenge of immunotherapy for pancreatic cancer. Dig Dis Sci. 2021; 66 (2): 359- 368.

[42] Raj D , Yang MH , Rodgers D , et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019; 68 (6): 1052- 1064.

[43] Wang M , Wu M , Liu X , et al. Pyroptosis remodeling tumor microenvironment to enhance pancreatic cancer immunotherapy driven by membrane anchoring photosensitizer. Adv Sci. 2022; 9 (29): e2202914.

[44] Rojas LA , Sethna Z , Soares KC , et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023; 618 (7963): 144- 150.

[45] Pushalkar S , Hundeyin M , Daley D , et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Disc. 2018; 8 (4): 403- 416.

[46] Zhang S , Wan X , Lv M , Li C , Chu Q , Wang G . TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized Medicine. EPMA J. 2022; 13 (3): 519- 534.

[47] Chen Y , Wang C , Song J , Xu R , Ruze R , Zhao Y . S100A2 is a prognostic biomarker involved in immune infiltration and predict immunotherapy response in pancreatic cancer. Front Immunol. 2021; 12: 758004.

[48] Kunzmann V , Siveke JT , Algül H , et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021; 6 (2): 128- 138.

[49] Hingorani SR , Zheng L , Bullock AJ , et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/ gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018; 36 (4): 359- 366.

[50] Von Hoff DD , Ervin T , Arena FP , et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369 (18): 1691- 1703.

[51] Javle M , Yu J , Garrett C , et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009; 100 (12): 1842- 1845.

[52] Ranieri G , Patruno R , Ruggieri E , Montemurro S , Valerio P , Ribatti D . Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem. 2006; 13 (16): 1845- 1857.

[53] Wei F , Su Y , Quan Y , et al. Anticoagulants enhance molecular and cellular immunotherapy of cancer by improving tumor microcirculation structure and function and redistributing tumor infiltrates. Clin Cancer Res. 2023; 29 (13): 2525- 2539.

[54] Buscail L , Bournet B , Cordelier P . Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020; 17 (3): 153- 168.

[55] Canon J , Rex K , Saiki AY , et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575 (7781): 217- 223.

[56] Jänne PA , Riely GJ , Gadgeel SM , et al. Adagrasib in non-small- cell lung cancer harboring a KRAS^G12C mutation. N Engl J Med. 2022; 387 (2): 120- 131.

[57] Skoulidis F , Li BT , Dy GK , et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021; 384 (25): 2371- 2381.

[58] Hong DS , Fakih MG , Strickler JH , et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020; 383 (13): 1207- 1217.

[59] Hofmann MH , Gerlach D , Misale S , Petronczki M , Kraut N . Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022; 12 (4): 924- 937.

[60] Koltun E , Cregg J , Rice MA , et al. First‐in‐class, orally bioavailable KRAS^G12V(ON) tri‐complex inhibitors, as single agents and in combinations, drive profound anti‐tumor activity in preclinical models of KRAS^G12V mutant cancers. Cancer Res. 2021; 81 (13_Supplement): 1260

[61] Hallin J , Bowcut V , Calinisan A , et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS^G12D inhibitor. Nat Med. 2022; 28 (10): 2171- 2182.

[62] Lietman CD , Johnson ML , McCormick F , Lindsay CR . More to the RAS story: KRAS^G12C inhibition, resistance mechanisms, and moving beyond KRAS^G12C. Am Soc Clin Oncol Educ Book. 2022; 42: 1- 13.

[63] Ma Y , Schulz B , Trakooljul N , et al. Inhibition of KRAS, MEK and PI3K demonstrate synergistic anti-tumor effects in pancreatic ductal adenocarcinoma cell lines. Cancers. 2022; 14 (18): 4467.

[64] Gu M , Gao Y , Chang P . KRAS mutation dictates the cancer immune environment in pancreatic ductal adenocarcinoma and other adenocarcinomas. Cancers. 2021; 13 (10): 2429.

[65] Mugarza E , van Maldegem F , Boumelha J , et al. Therapeutic KRAS^G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022; 8 (29): eabm8780.

[66] Zhao Y , Murciano-Goroff YR , Xue JY , et al. Diverse alterations associated with resistance to KRAS^G12C inhibition. Nature. 2021; 599 (7886): 679- 683.

[67] Awad MM , Liu S , Rybkin II , et al. Acquired resistance to KRAS^G12C inhibition in cancer. N Engl J Med. 2021; 384 (25): 2382- 2393.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.